# Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease

> **NCT02819284** · PHASE3 · COMPLETED · sponsor: **Kala Pharmaceuticals, Inc.** · enrollment: 909 (actual)

## Conditions studied

- Dry Eye Syndromes
- Keratoconjunctivitis Sicca

## Interventions

- **DRUG:** KPI-121 0.25% Ophthalmic Suspension
- **DRUG:** Vehicle of KPI-121 0.25% Ophthalmic Suspension

## Key facts

- **NCT ID:** NCT02819284
- **Lead sponsor:** Kala Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2017-09
- **Final completion:** 2017-09
- **Target enrollment:** 909 (ACTUAL)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02819284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02819284, "Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02819284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*